LataMed AI Corp. Authorizes New Series C Preferred Stock with Significant Voting Power
CCTC has more than doubled off its 52-week low of $0.265.
Summary
LataMed AI Corp. has authorized a new Series C Preferred Stock with 5 million shares, each carrying 20 votes, and strong protective provisions, potentially impacting common shareholder control.
Key Events · Corporate Governance and Compliance · CCTC
-
New Preferred Stock Authorized
The Board of Directors approved the designation of 5,000,000 shares of Series C Voting Preferred Stock.
-
Significant Voting Rights
Each Series C Preferred share is entitled to 20 votes, voting together with common stock as a single class.
-
Strong Protective Provisions
Holders of Series C Preferred Stock will have veto power over key corporate actions, including creating senior capital stock, amending Series C terms, and company liquidation.
-
Non-Convertible Shares
The Series C Preferred Stock is non-convertible, meaning it will not directly dilute common shares through conversion.
Analysis · CCTC · Technology
The company's Board of Directors has authorized a new Series C Voting Preferred Stock, which, if issued, would carry substantial voting rights (20 votes per share) and significant protective provisions. This move fundamentally alters the company's capital structure and could enable a shift in corporate control or facilitate a strategic financing round. Investors should monitor for any future issuance of these shares, as it could significantly impact common shareholder voting power and influence major corporate decisions.
At the time of this filing, CCTC was trading at $2.18 on OTC in the Technology sector, with a market capitalization of approximately $126.9M. The 52-week trading range was $0.27 to $675.01. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.